SecBot SecBot
8-K ·Filed May 5, 2026

RYTM

RHYTHM PHARMACEUTICALS, INC.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001628280-26-030136
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The strong IMCIVREE launch in acquired HO and EU approval are positive catalysts, but the EMANATE trial failure and widening losses create uncertainty. Watch for PMDA decision in H2 2026 and upcoming data readouts from PWS and RM-718 trials. The stock may trade on execution of the HO launch ramp rather than near-term profitability.

DirectionMixed
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M (up 59% YoY from $37.7M) and GAAP EPS of -$0.83, beating consensus estimates of -$0.86. The U.S. launch of IMCIVREE for acquired hypothalamic obesity is off to a strong start with >150 patient start forms in the first six weeks, and European Commission marketing authorization was granted in May 2026. However, net loss widened to -$56.7M from -$50.8M, and the Phase 3 EMANATE trial failed its primary endpoint, tempering the overall outlook.

Key Financial Metrics

EPS
−$0.83
est −$0.86 · +3.5%
Revenue
$60.1M
est $56.1M · +7.2% · +59.4% YoY
Rating
beat
Gross Margin
88.1%

Key Facts

  • Q1 2026 net product revenue of $60.1M, up 59% YoY from $37.7M
  • GAAP EPS of -$0.83 vs consensus -$0.86 (3.6% beat)
  • Net loss attributable to common stockholders widened to -$56.7M from -$50.8M YoY
  • U.S. launch of IMCIVREE for acquired HO: >150 patient start forms in first 6 weeks post-FDA approval (March 19, 2026)
  • European Commission granted marketing authorization for IMCIVREE in acquired HO on May 1, 2026
  • Phase 3 EMANATE trial did not achieve primary endpoint in any of four substudies
  • Cash, cash equivalents and short-term investments of $340.6M as of March 31, 2026
  • 2026 Non-GAAP operating expense guidance of $385M-$415M
  • Japanese NDA for setmelanotide in acquired HO under PMDA review, decision expected H2 2026

Financial Impact

Revenue growth of $22.4M YoY (+59%) driven by IMCIVREE sales; net loss increased by $5.9M YoY

revenuenet losscash position

Risk Factors

  • Phase 3 EMANATE trial failure in genetically caused MC4R pathway diseases limits pipeline optionality
  • Net loss widening and increasing SG&A expenses ($63.6M vs $39.1M YoY) pressure cash runway despite $340.6M position
  • Dependence on acquired HO launch success for revenue growth; competitive and reimbursement risks
  • Japanese PMDA decision and EU country-level launches subject to regulatory and commercial uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-030136
Document: 0001628280-26-030136-index-headers.html0001628280-26-030136
Document: 0001628280-26-030136-index.html0001628280-26-030136
Document: 0001628280-26-030136.txt0001628280-26-030136
8-K Data (Synthetic)0001628280-26-030136

Track record

26 reports on RYTM

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026